ライフサイエンスコーパス: receptor type

1 ccurring within dimers comprised of the same receptor type.

2 cell firing, and identification of dopamine receptor type.

3 ansmitter release, cell firing, and dopamine-receptor type.

4 nnervation to this sense organ employs other receptor types.

5 tors and also as versatile ligands for other receptor types.

6 y tracts, with similar distributions of both receptor types.

7 ting that GABA actions can be local for both receptor types.

8 Activin A receptor type 1 (ACVR1) is a BMP type 1 receptor essenti

9 dentified one important gene, angiotensin II receptor type 1 (AGTR1), in the Ca2+/AT-IIR/alpha-AR sig

10 2 downregulation enhances the angiotensin II receptor type 1 (AT(1) R) axis associated with oxidative

11 in minutes by pharmacological angiotensin-II receptor type 1 (AT1 R) blockade.

12 l evidence indicates that the angiotensin II receptor type 1 (AT1 R) is inherently mechanosensitive a

13 s been shown to interact with angiotensin II receptor type 1 (AT1).

14 rize a GPCR-TRP channel pair, angiotensin II receptor type 1 (AT1R), and transient receptor potential

15 estin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), stimulates acute catecholamine s

16 r calcium release mediated by angiotensin II receptor type 1 (AT1R).

17 or signalling through BMEC AT2R, HSCP Ang-II receptor type 1 (AT1R)/AT2R or HSC/P RhoA, but not by in

18 Experiments with cannabinoid receptor type 1 (CB(1))/MGL double-KO mice revealed that

19 ligomerization between the GPCRs cannabinoid receptor type 1 (CB(1)R) and 5-hydroxytryptamine 2A (5-H

20 otoxemic mice were reversed by a cannabinoid receptor type 1 (CB(1)R) inverse agonist (SR141716), and

21 d neuroprotective efficacies via cannabinoid receptor type 1 (CB1) or type 2 (CB2) or via peroxisome

22 al maturation, downregulation of cannabinoid receptor type 1 (CB1) receptors, and impaired neurite ou

23 nist/inverse agonist activity at cannabinoid receptor type 1 (CB1R) and inhibitory effect on inducibl

24 The cannabinoid receptor type 1 (CB1R) colocalized with TRPV1:tdTomato e

25 among the highest expression of cannabinoid receptor type 1 (CB1r) in the brain.

26 models, peripherally restricted cannabinoid receptor type 1 (CB1R) inhibitors, which are devoid of t

27 oseful movements was reverted by cannabinoid receptor type 1 (CB1r) manipulations directly into the S

28 OX-A receptor type 1 (OX-1R) and cannabinoid receptor type 1 (CB1R) on the plasma membrane.

29 Cannabinoid receptor type 1 (CB1R) plays a critical role in the regu

30 ha2A-adrenergic receptor, GABAB, cannabinoid receptor type 1 (CB1R), and dopamine receptor type 2.

31 aptic transmission in the PL via cannabinoid receptor type 1 (CB1R)- and 2-arachidonoylglycerol-depen

32 we aimed to further evaluate the cannabinoid receptor type 1 (CB1R)-mediated mechanisms in a postnata

33 ne receptor type 4 (CXCR4) and C-C chemokine receptor type 1 (CCR1), which are the receptors of SDF-1

34 ide driven by corticotropin-releasing factor receptor type 1 (CRF1) potentiation of the anandamide ca

35 f the class B corticotropin-releasing factor receptor type 1 (CRF1R) with two peptide agonists and th

36 eurons (MSN), expressing either the dopamine receptor type 1 (D(1) -R MSN) and forming the direct, mo

37 edium spiny neurons expressing dopamine (DA) receptor type 1 (D1-MSNs) and type 2 (D2-MSNs) of the NA

38 mushroom spines of MSNs expressing dopamine receptor type 1 (D1-MSNs).

39 rojection neurons (SPNs) expressing dopamine receptor type 1 (D1-SPNs) or 2 (D2-SPNs) in mice, we dem

40 s Gadd45b mRNA expression through a dopamine receptor type 1 (DRD1)-dependent mechanism.

41 ablation of this receptor-type, but not FGF receptor type 1 (FGFR1), resulted in attenuation of myel

42 ta knockout (KO) mice and perioperative IL-1 receptor type 1 (IL-1R1) blockade with the drug anakinra

43 rs, IL-1 receptor accessory protein and IL-1 receptor type 1 (IL-1R1), and enhanced sensitivity to IL

44 pertussis toxin administration leads to IL-1 receptor type 1 (IL-1R1)-dependent IL-1beta expression b

45 ticulum protein inositol 1,4,5-trisphosphate receptor type 1 (IP3R1), which triggers proteasomal degr

46 The lysophosphatidic acid receptor type 1 (LPA1) is 1 of 6 known receptors of the

47 f a dimeric GPCR, the metabotropic glutamate receptor type 1 (mGluR1), by two entirely different meth

48 ar learning induced a metabotropic glutamate receptor type 1 (mGluR1)-mediated late long-term potenti

49 The neuropeptide receptor neuropeptide Y receptor type 1 (Npy1r) amalgamated multiple cell types

50 X-A)-expressing inputs and express both OX-A receptor type 1 (OX-1R) and cannabinoid receptor type 1

51 Here we show that signaling at orexin receptor type 1 (OxR1) in the VTA is required for morphi

52 microscopy (cryo-EM) snapshots of ryanodine receptor type 1 (RyR1), a calcium-activated calcium chan

53 ed the effects of BPA and TBBPA on ryanodine receptor type 1 (RyR1), dihydropyridine receptor (DHPR),

54 red the binding of the capsid to transferrin receptor type 1 (TfR), particularly during virus dissoci

55 (VEGFR), vascular endothelial growth factor receptor type 1 (VEGFR1), vascular endothelial growth fa

56 rarenal angiotensinogen production and ANGII receptor type 1 activation that are associated with incr

57 pocampal slices, and hippocampal cannabinoid receptor type 1 and brain-derived neurotrophic factor (B

58 RAP; IL1R3) is a coreceptor of interleukin-1 receptor type 1 and has been found upregulated on CML st

59 diated in part through IL-1, because an IL-1 receptor type 1 antagonist ameliorated the effects of LT

60 can be reversed acutely by an angiotensin-II receptor type 1 antagonist.

61 nverting enzyme inhibitors or angiotensin-II receptor type 1 blockers may be less effective and suppo

62 nverting enzyme inhibitors or angiotensin-II receptor type 1 blockers.

63 553Leu]) in the inositol 1,4,5-trisphosphate receptor type 1 gene (ITPR1).

64 complex with transforming growth factor beta receptor type 1 kinase domain were determined by X-ray c

65 eased placental HIF-1alpha in an angiotensin receptor type 1 receptor agonistic autoantibody (AT(1) -

66 -129/Sv-4A11(+/+), and blockade of the ANGII receptor type 1 with losartan normalizes BP.

67 at central cannabinoid receptor (cannabinoid receptor type 1) agonists decrease the power of neural o

68 a interacts with its receptor (interleukin 1 receptor type 1) on hematopoietic stem and progenitor ce

69 oexcitation is independent of angiotensin II receptor type 1, oxytocin, ionotropic glutamate and GABA

70 ntibody antagonist of metabotropic glutamate receptor type 1.

71 ACE2 together with angiotensin receptor types 1 and 2 and ACE2 are components of the re

72 angiotensin II, which activates angiotensin receptor types 1 and 2, and angiotensin 1-7 and alamandi

73 ated genes included the innate interleukin 1 receptor, type 1 and the antimicrobial peptide(AMP) adre

74 incipal neurons were dependent on muscarinic receptors type 1, engaging different intracellular mecha

75 therapeutic targets include the cannabinoid receptors, type 1 and 2, as well as biosynthetic and cat

76 Cannabinoid receptor type-1 (CB1) is known to have a substantial imp

77 Cannabinoid receptor type-1 (CB1) plays a crucial role in controllin

78 ion of NAc FSIs that express the cannabinoid receptor type-1 (CB1).

79 Here we show that muscarinic receptor type-1 (Chrm1) signaling in the hypothalamus pr

80 CRH expression, and blocking hippocampal CRH receptor type-1 (CRHR1) immediately following early-life

81 ic binding to the host receptor, transferrin receptor type-1 (TfR).

82 pathogenic protein tyrosine phosphatase, non-receptor type 11 (PTPN11) variant and variants of uncert

83 of PTPN14 (protein tyrosine phosphatase, non-receptor type 14) which, in turn, regulated the Hippo pa

84 al ligand of the growth hormone secretagogue receptor type 1a (GHS-R1a), is mainly secreted from the

85 receptor type 1L, bone morphogenetic protein receptor type 1A, and bone morphogenetic protein recepto

86 tivating two high-affinity G-protein-coupled receptors, type 1A (MT(1)) and type 1B (MT(2))(3,6).

87 of SMAD2 via the type 1 receptors activin A receptor type 1B (ALK4), TGFBR1, and activin A receptor

88 KEY POINTS: The angiotensin II receptor type 1b (AT1 Rb ) is the primary sensor of intr

89 ptor type 1A, and bone morphogenetic protein receptor type 1B and phosphorylation of SMAD2 by ALK4, T

90 se-related microRNAs targeting the activin A receptor type 1C (ACVR1C), a component of the transformi

91 ceptor type 1B (ALK4), TGFBR1, and activin A receptor type 1C (ALK7).

92 diated phosphorylation of SMAD1 by activin A receptor type 1L, bone morphogenetic protein receptor ty

93 growth factor beta (47%) and angiotensin II receptor type 2 (132%), 27% less elastin as well as conc

94 The first potent leukotriene B4 (LTB4) receptor type 2 (BLT2) agonists, endogenous 12(S)-hydrox

95 Expression of bone morphogenetic protein receptor type 2 (BMPR2) and its target, collagen IV, sig

96 gene encoding the bone morphogenetic protein receptor type 2 (BMPR2) are the commonest genetic cause

97 mutations in the bone morphogenetic protein receptor type 2 (BMPR2) gene and patients with idiopathi

98 e mutation in the bone morphogenetic protein receptor type 2 (BMPR2) gene, right ventricle (RV) dysfu

99 MO, T cells, and expression of C-C chemokine receptor type 2 (Ccr2) and C-C chemokine receptor type 5

100 stream to Fyn, MCP1 stimulated C-C chemokine receptor type 2 (CCR2) and Gi/o and inhibition of either

101 C-C chemokine receptor type 2 (CCR2) antagonist and clodronate (CLD) w

102 tients with a special focus on C-C chemokine receptor type 2 (CCR2) expressions on classical Mo.

103 C-C chemokine receptor type 2 (CCR2) is expressed by active hepatic st

104 C-C chemokine receptor type 2 (CCR2) is expressed on monocytes and fac

105 or pharmacologic inhibition of CC chemokine receptor type 2 (CCR2) reduced macrophage (MP) infiltrat

106 40-B, a selective inhibitor of C-C chemokine receptor type 2 (CCR2), could further reduce albuminuria

107 generated MDSC were expressed C-C chemokine receptor type 2 (CCR2), which was enhanced by exposure t

108 Purpose To characterize a chemokine receptor type 2 (CCR2)-binding peptide adapted for use a

109 A C-C chemokine receptor type 2 (CCR2)-positive macrophage subpopulation

110 Complement receptor type 2 (CR2)/CD21 plays a key role in the devel

111 ivated C3b, which are ligands for complement receptor type 2 (CR2/CD21), the aim of the current study

112 expression of corticotropin-releasing factor receptor type 2 (CRFR2) to be associated with post-traum

113 ect, movement-promoting pathway, or dopamine receptor type 2 (D(2) -R MSN), forming the indirect move

114 naptic responses in MSNs expressing dopamine receptor type 2 (D2-MSNs).

115 Here, we show that FGF receptor type 2 (FGFR2) is highly enriched at the parano

116 xplored role of the hydroxyl carboxylic acid receptor type 2 (HCAR2) in 2 models of neuropathic pain.

117 patients) and human epidermal growth factor receptor type 2 (HER2) (in 15,418 patients in trials wit

118 lar imaging of human epidermal growth factor receptor type 2 (HER2) expression may help to stratify b

119 The human growth factor receptor type 2 (HER2) is overexpressed in breast as wel

120 receptor (HR)/ human epidermal growth factor receptor type 2 (HER2) status.

121 effective for human epidermal growth factor receptor type 2 (HER2)-positive breast cancer but is ass

122 rated that the human epidermal growth factor receptor type 2 (HER2)-targeting ADAPT6 labeled with rad

123 31)I-GMIB-anti-human epidermal growth factor receptor type 2 (HER2)-VHH1 is a targeted radionuclide t

124 agonist (IL-1Ra) and the decoy receptor IL-1 receptor type 2 (IL-1R2).

125 coupling, using the muscarinic acetylcholine receptor type 2 (M2R) as the primary Gi/o-coupling recep

126 and-binding domain of metabotropic glutamate receptor type 2 (mGluR2).

127 Protein tyrosine phosphatase non-receptor type 2 (PTPN2) protects the IEC barrier from in

128 Ca(2+) leak via ryanodine receptor type 2 (RyR2) can cause potentially fatal arrhy

129 erent forms of AF, have implicated ryanodine receptor type 2 (RyR2) dysfunction and enhanced spontane

130 l stimulation and nearly abolished ryanodine receptor type 2 (RyR2)-dependent sarcoplasmic Ca(2+) lea

131 Somatostatin receptor type 2 (SSTR2) expression and (68)Ga-DOTATOC up

132 In this study, we analyzed TGFbeta receptor type 2 (TGFBR2) expression and correlated it wi

133 by Tregs was fully abolished by blocking TNF receptor type 2 (TNFR2) or by using TNF-deficient donor

134 Pharmacological inhibition of VEGF receptor Type 2 (VEGFR-2) signaling attenuated mechanica

135 d role of vascular endothelial growth factor receptor type 2 (VEGFR2) in the regulation of gingival v

136 ffects on vascular endothelial growth factor receptor type 2 (VEGFR2) phosphorylation, tumor volume,

137 (VEGFR1), vascular endothelial growth factor receptor type 2 (VEGFR2), and vascular endothelial growt

138 lusters of ILC3 that selectively express VIP receptor type 2 (VIPR2; also known as VPAC2).

139 onformational dynamics of the neuropeptide Y receptor type 2 (Y2R) during activation was investigated

140 1 receptor blockade diminished C-C chemokine receptor type 2 [CCR2(neg) (Ly6C(lo))] monocytes, attenu

141 of immunoprecipitated JMC proteins ryanodine receptor type 2 and junctophilin-2 (JPH2) followed by ma

142 of immunoprecipitated JMC proteins ryanodine receptor type 2 and junctophilin-2 (JPH2) followed by ma

143 lt of increased activity of mutant ryanodine receptor type 2 channels, sarcoplasmic reticulum Ca(2+)

144 +) release events from hyperactive ryanodine receptor type 2 channels.

145 unexplored role of hydroxyl carboxylic acid receptor type 2 in the pathophysiology of neuropathic pa

146 lar similarity to bone morphogenetic protein receptor type 2 mutation-associated heritable pulmonary

147 ing miRYR2-U10 in correcting RyR2 (Ryanodine Receptor type 2 protein) function after in vivo delivery

148 ha2A-adrenergic receptor, GABAB, or dopamine receptor type 2 receptors did not reveal any interaction

149 ortantly, pharmacological inhibition of VEGF receptor Type 2 signaling in rats causes analgesia and b

150 is caused by impairment of vasopressin (VP) receptor type 2 signaling.

151 Expression of cannabinoid receptor Type 2 was reported in osteoblasts and osteocla

152 compatibility complex II/C-C motif chemokine receptor type 2) macrophages expressed higher levels of

153 is largely populated by CCR2- (C-C chemokine receptor type 2) macrophages of embryonic descent.

154 BMPR2 (bone morphogenetic protein receptor type 2) mutations account for most familial PAH

155 Delta9-THC receptors, including cannabinoid receptor type 2, TRPV1, GPR18, GPR55, and GPR119.

156 g PIDs are mediated by inositol triphosphate receptor type 2-dependent (IP3R2-dependent) release from

157 tages of Huntington's disease, when dopamine receptor type 2-expressing striatal medium spiny neurons

158 Ca(2+)-cycling proteins including ryanodine receptor type 2.

159 ts angiogenesis through activation of the DA receptor type 2.

160 abinoid receptor type 1 (CB1R), and dopamine receptor type 2.

161 mone receptor, human epidermal growth factor receptor type 2/neu, Ki-67) were extracted and compared

162 Cannabinoid receptors type 2 (CB2) represent a target with increasin

163 anogenic effect of ATP to binding purinergic receptors type 2 X7 (P2X7), which are expressed on human

164 mRNA for sweet receptor subunits T1R (Taste receptor type) 2 and 3, as well as other markers associa

165 oV-2) receptor angiotensin-converting enzyme receptor type-2 (ACE2) and can be infected with virus.

166 This activity occurred within dopamine receptor type-2 (D2R)-expressing cells in the nucleus ac

167 TGF-beta receptor type-2 (TGFBR2) is the ligand-binding receptor

168 the present study, we show that vasopressin receptor type-2 (V2R) is localized to cilia in kidney ep

169 n an astrocyte-specific inositol 3-phosphate receptor type-2 knockout mouse, near-infrared light-indu

170 ncreased, and PKA sites Ser2808 in ryanodine receptor type-2, Ser16 in phospholamban, and Ser23/24 in

171 blance to physiological inositol 3-phosphate receptor type-2-independent Ca(2+) signals, whereas soma

172 variant in protein tyrosine phosphatase non-receptor type 22 (PTPN22) is associated with reduced ris

173 ractions with the type II receptor activin A receptor type 2B (ActRIIB).

174 e (SS) and HCV, presence of anti- muscarinic receptor type 3 (M3R) antibodies in SS, the role that M3

175 FR2), and vascular endothelial growth factor receptor type 3 (VEGFR3).

176 b/CD18 beta2 integrin heterodimer complement receptor type 3/Mac-1.

177 lude C17orf104, inositol 1,4,5-trisphosphate receptor, type 3 (ITPR3), and discoidin domain receptor

178 mokine receptor type 5 and chemokine-related receptor type 4 (CCR5 and CXCR4) on peripheral blood mon

179 in-coupled receptors (GPCRs) C-X-C chemokine receptor type 4 (CXCR4) and atypical chemokine receptor

180 mpaired by the inhibitors of C-X-C chemokine receptor type 4 (CXCR4) and C-C chemokine receptor type

181 The C-X-C motif chemokine receptor type 4 (CXCR4) and the atypical chemokine recep

182 including overexpression of C-X-C chemokine receptor type 4 (CXCR4) and upregulation of plasminogen

183 onstrated that antagonism of C-X-C chemokine receptor type 4 (CXCR4) by plerixafor (AMD3100) can decr

184 The human protein tyrosine phosphatase non-receptor type 4 (PTPN4) prevents cell death induction in

185 stromal cell-derived 1 alpha receptor (C-X-C receptor type 4 or CXCR4) using AMD3100 prevented the po

186 ated with the number of dermal C-C chemokine receptor type 4(+) T helper type 2 cells, IL-17(+) cells

187 , were antagonized by CXCR4 (C-X-C chemokine receptor type 4) and regulated the outer topology of neu

188 olesterol to the G protein coupled chemokine receptor type 4, and the identification of permeation pa

189 en and elastin staining, and C-X-C chemokine receptor type 4, nuclear factor kappa beta, and tartrate

190 y-stimulating factor and the C-X-C chemokine receptor type 4.

191 (Fuzeon, enfuvirtide) and the C-C chemokine receptor type 5 (CCR5) blocker maraviroc (Selzentry).

192 ine receptor type 2 (Ccr2) and C-C chemokine receptor type 5 (Ccr5) in the livers of patients with AL

193 The C-C chemokine receptor Type 5 (CCR5) is a key receptor for human immun

194 nstrated that ORM1 can bind to C-C chemokine receptor type 5 (CCR5) on muscle cells and deletion of t

195 C-C chemokine receptor type 5 (CCR5) serves as a co-receptor for Human

196 he G-protein-coupled receptor, C-C chemokine receptor type 5 (CCR5), in human disease since ancient t

197 opulation is enriched with a C-X-C chemokine receptor type 5 (CXCR5)(+)CD4(+) TFH precursor phenotype

198 global reductions in metabotropic glutamate receptor type 5 (mGluR5) binding in smokers and recent e

199 through activation of metabotropic glutamate receptor type 5 (mGluR5) signaling and that this astrocy

200 sue concentrations of metabotropic glutamate receptor type 5 (mGluR5).

201 Protein tyrosine phosphatase non-receptor type 5 (PTPN5, STEP) is a brain specific phosph

202 rentiation 4 (CD4) and coreceptors chemokine receptor type 5 and chemokine-related receptor type 4 (C

203 c CD8 T cells express CXCR5 (C-X-C chemokine receptor type 5, a chemokine receptor required for homin

204 s in the activation muscarinic acetylcholine receptors type 5, which mediate potentiation of dopamine

205 fied in the protein tyrosine phosphatase non-receptor type 6 (PTPN6) gene, also known as SHP-1, an im

206 (ACKR3), previously known as C-X-C chemokine receptor type 7 (CXCR7), has emerged as a key player in

207 CC chemokine receptor type 9 (CCR9) activation by CCL25 plays a key r

208 iated with increased glomerular endothelin-1 receptor type A (Ednra) expression and increased circula

209 two G protein-coupled receptors - endothelin receptor type A (ET(A)) and endothelin receptor type B (

210 BMSCs was attenuated by blocking endothelin receptor type A (ETAR) and/or endothelin receptor type B

211 Similar to the widely used GABA receptor type A (GABA(A)) antagonist picrotoxinin, TETS

212 d cells, we further identified the scavenger receptor type A member I (SR-AI) to be a macrophage-spec

213 the pore of the alpha(2)beta(3)gamma(2) GABA receptor type A receptor at the so-called T6' ring, wher

214 the signaling receptor, natriuretic peptide receptor type A, to the clearance receptor, nprc, was in

215 ants influencing expression of EPHA2 (Ephrin-receptor Type-A2), a tyrosine kinase receptor that has b

216 spite the little structural similarity, both receptor types activate similar responses with different

217 S/heparin and NRP-1 may dictate the specific receptor type activated by VEGF and ultimately determine

218 esult not possible from activation of either receptor type alone.

219 Rs by reversibly applying antagonists to two receptor types, alpha7 and alpha4beta2.

220 cally important to identify the specific FGF receptor type and its downstream signaling molecules in

221 The specificity of receptor type and mechanism of interaction has not yet b

222 Interactions among these receptor types and their subsequent membrane trafficking

223 We find that specific receptor types are expressed by distinct combinations of

224 helin receptor type A (ET(A)) and endothelin receptor type B (ET(B)) - with equal affinity, whereas E

225 The endothelin receptor type B (ETBR) regulates water and electrolyte b

226 lin receptor type A (ETAR) and/or endothelin receptor type B (ETBR).

227 helin 3 (EDN3), its receptor (the endothelin receptor type B [EDNRB]), and the transcription factors

228 lar pathway whereby membrane-bound scavenger receptor type B-1 (SR-B1) in parent cells becomes incorp

229 eceptor for cholesterol-rich HDLs, scavenger receptor type B1 (SCARB1).

230 tor usage is highly heterogeneous, with some receptor types being orders of magnitude more abundant t

231 Conditional ablation of this receptor-type, but not FGF receptor type 1 (FGFR1), resu

232 ogical manipulation to reveal the individual receptor type contributions, we find that m2 muscarinic

233 efore, blocking detrimental activity of both receptor types could be therapeutically beneficial.

234 he model also suggests that overly sensitive receptor types could dominate the entire response and ma

235 pithelial neural network of Beroe, with five receptor types, covers the entire body surface and expan

236 ndicates that spiking pattern, regardless of receptor type, determines vibrotactile frequency percept

237 t the first high-resolution structure of the receptor type found in muscle-endplate membrane and in t

238 Protein-tyrosine phosphatase receptor type G (RPTPgamma/PTPRG) interacts in vitro wit

239 H) and the peroxisome proliferator-activated receptor type gamma (PPARgamma).

240 cient trafficking of a sensory receptor, the receptor-type guanylate cyclase GCY-9, to cilia in chemo

241 rent affinity of striatal D1 and D2 dopamine receptor types has been argued to constrain the D1 and D

242 sized that disrupting the cognate type I IFN receptor (type I IFN alpha/beta receptor [IFNAR]) to int

243 in homolog 1 (DMH1) or CRISPR/Cas9 activin A receptor type I (ACVR1) knockout in OPCs.

244 ting enzyme (ACE) inhibitors and angiotensin receptor type I (AT(1)R) antagonists.

245 tokine family that signals through the IL-20 receptor type I (IL-20Ralpha:IL-20Rbeta), is a cytokine

246 Ryanodine receptor type I (RYR1)-related myopathies (RYR1 RM) are

247 o an increase in the expression of the AngII receptor type I a and activation of signaling at 100-fol

248 factor kappaB signaling, and increases AngII receptor type I a expression, thus potentiating AngII si

249 signaling and increases expression of AngII receptor type I a.

250 Par2 expression to repress sequentially IL-1 receptor type I and Sema3A expression.

251 Interleukin-1 receptor type I knockout mice, which display braked immu

252 signaling, including the IL-6 receptor, IL-1 receptor type I, and IL-1 receptor type II.

253 Ryanodine receptor type I-related myopathies (RYR1-RMs) are a comm

254 orphogenic protein receptor kinase activin A receptor, type I (ACVR1), and the subsequent reduction o

255 for binding to intact, functional ryanodine receptors type I (RyR1) and II (RyR2) from skeletal and

256 Strikingly, we found that IFN-alpha/beta receptor (type-I IFN receptor) was expressed by primary

257 s contain somatic mutations in the activin A receptor type IB (ACVR1B) gene, indicating that ACVR1B c

258 (Type III) cell transmitter, but not ATP, a Receptor (Type II) cell transmitter.

259 In contrast, Receptor (Type II) taste cells rarely (4%) responded to

260 on factor 11 (GDF11) through soluble activin receptor type II (ActRII) ligand traps or neutralizing a

261 rent from AT(1)R, in particular, angiotensin receptor type II (AT(2)R), resulting in biological and p

262 gene encoding the bone morphogenetic protein receptor type II (BMPR2) are the commonest genetic cause

263 L-6 receptor, IL-1 receptor type I, and IL-1 receptor type II.

264 with mutations in bone morphogenetic protein receptor type II.

265 at drugs that modulate the two dominant GABA receptor types in the brain, GABA(A) (clobazam) and GABA

266 nd mesogleal) and the structure of different receptor types in the comb jelly Beroe abyssicola-the vo

267 nformation depends strongly on the number of receptor types included in the primacy representation, b

268 conjunction with their cognate PLXNB family receptors, type IV members have been increasingly shown

269 ine phosphatase protein tyrosine phosphatase receptor type J (PTPRJ), a known extracellular signal-re

270 umor suppressor Protein tyrosine phosphatase receptor-type kappa (PTPRK), as a Wnt inhibitor in human

271 ecific receptor states, rather than specific receptor types, may be a viable strategy for future drug

272 quencies > 60 Hz), subserved by two distinct receptor types (Meissner's and Pacinian corpuscle, respe

273 milar region on all three traditional opioid receptor types (micro-OR, delta-OR, and kappa-OR).

274 se peptides binds to all three of the opioid receptor types (mu, delta, or kappa), albeit with differ

275 ing networks where information from numerous receptor types passes through a small set of signaling p

276 The exclusion of large receptor-type phosphatases was observed on the soft bila

277 These three genes encode a non-receptor type protein tyrosine phosphatase, a serine/thr

278 Receptor type protein tyrosine phosphatase-sigma (PTPsig

279 Receptor-type protein tyrosine phosphatase alpha (RPTPal

280 Mutations of PTPRD, a receptor-type protein tyrosine phosphatase regulating ce

281 ase (STEP), and protein-tyrosine phosphatase receptor type R (PTPRR).

282 fear, and anxiety, and the specific cell and receptor types responsible is an active area of investig

283 e transferrin receptor and several glutamate receptor types, resulting in their appearance in the axo

284 Multiple immune receptor types rewire metabolic pathways as a key part o

285 e the minimal structural differences between receptor types, selectivity can be achieved in a number

286 itivities of L and M cones were, on average, receptor-type specific, but individual cone thresholds v

287 zebrafish single cell RGCs were treated with receptor-type-specific antagonists and, respectively, wi

288 Our data indicate a rapid, receptor-type-specific, two-step binding and activation

289 g, where the odor identity is encoded by the receptor types that respond earliest, might provide a co

290 mined the average quantity of each glutamate receptor type, their nanoscale organization, and their r

291 ll sizes to have a large number of olfactory receptor types, to maintain olfactory precision in their

292 ir C-terminal tail, and are activated by the receptor-type tyrosine phosphatase PTPRJ (CD148, DEP-1),

293 ivity and is activated in osteoclasts by the receptor-type tyrosine phosphatase PTPROt.

294 We investigated the role of PTPRF, a receptor-type tyrosine phosphatase, in regulating Wnt si

295 Because most receptor-type tyrosine phosphatases contain potential ph

296 n AMR, as did glomerular nephrin (NPHS1) and receptor-type tyrosine-phosphatase O (PTPRO).

297 cells express the putative HCO(3)(-)-sensor receptor-type tyrosine-protein phosphatase RPTPgamma, wh

298 inhibition of cell-cell contacts through the receptor-type tyrosine-protein phosphatases kappa led to

299 postsynaptic partners, the neurotransmitter receptor type used to receive input from presynaptic neu

300 ng the reach of new medicine design to novel receptor types with potential therapeutic value.